Clinical Trial

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

Recruiting
View on ClinicalTrials.gov →
Summary
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-04-06; most recent amendment 2025-06-10.
Trial Details
NCT Number NCT04340024
Lead Sponsor National Cancer Centre, Singapore
Collaborators: National Medical Research Council (NMRC), Singapore, Duke-NUS Graduate Medical School, Ferring Pharmaceuticals, ImmunoSCAPE, Decipher Biosciences
Conditions Nasopharyngeal Cancer, Prostate Cancer, Other Cancer
Enrollment 5,000 participants
Start Date 2015-09-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-11